On July 14, 2026 HUYABIO International reported statistically significant and clinically meaningful topline results from its global Phase 3 clinical trial evaluating HBI-8000 in combination with nivolumab for patients with advanced melanoma, bringing the company one step closer to a potential new frontline treatment option for one of the deadliest forms of skin cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study met its primary endpoint, with patients receiving HBI-8000 in combination with nivolumab achieving a median progression-free survival of 11.7 months, compared with 7.4 months for patients receiving nivolumab plus placebo, a statistically significant improvement in progression-free survival of 58%. Further statistical analysis is in progress to identify in detail the strong efficacy advantage of HBI-8000.
The randomized global Phase 3 trial enrolled 404 patients across 15 countries, representing HUYABIO’s largest oncology study to date. HBI-8000 is an oral drug that has received regulatory approval for lymphoma in China and Japan. It has been prescribed to over 90,000 patients and so has a well established safety record.
"These results represent an exciting milestone for patients and the future of melanoma treatment," Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO, said. "Although immunotherapy has dramatically improved outcomes, many patients still need better options. We believe HBI-8000 will become an important addition to the standard of care, helping physicians improve outcomes while bringing new hope to patients and their families."
Data from HBI-8000-303 will be presented at future medical meetings.
(Press release, HUYA Bioscience, JUL 14, 2026, View Source [SID1234669212])